Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, ba...

Full description

Bibliographic Details
Main Authors: Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, Seungtaek Kim, Léa Luciani, Grégory Moureau, Soonju Park, Paul-Rémi Pétit, David Shum, Thanaporn Wattanakul, Birgit Weynand, Laurent Fraisse, Jean-Robert Ioset, Charles E. Mowbray, Andrew Owen, Richard M. Hoglund, Joel Tarning, Xavier de Lamballerie, Antoine Nougairède, Johan Neyts, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Microorganisms
Subjects:
COVID-19
drug repurposing
translational medicine
pandemics
clinical trials
Online Access:https://www.mdpi.com/2076-2607/10/8/1639

Similar Items

Similar Items